Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Quanta, Inc. (QNTA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0032-0.0004 (-12.50%)
At close: 11:29AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0036
Open0.0033
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0030 - 0.0037
52 Week Range0.0029 - 0.1134
Volume1,441,584
Avg. Volume3,558,617
Market Cap676,408
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateNov 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Medolife Rx Schedules Conference Call with Investment Community to Discuss New Updates and Answer Questions

    BURBANK, CA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biotech company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC QB: QNTA), announced today that it has scheduled a conference call with investors for Thursday, May 12. Conference Call Topics: Potential investment infusion; Further developments on FDA Pre-IND application #150335 for Escozine as a COVID-19 treatme

  • GlobeNewswire

    Medolife Rx Announces Changes to Management and Improvements to AELIA’s Marketing Efforts

    BURBANK, CA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s

  • GlobeNewswire

    Medolife Rx Submits Final Clinical Trial Data for Escozine Approval as a COVID-19 Treatment in The Dominican Republic

    BURBANK, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, whi

Advertisement
Advertisement